MMSL 2017, 86(3):114-121 | DOI: 10.31482/mmsl.2017.019

CHEMOTERAPEUTIKUM DAPSON - ZÁKLADNÍ CHARAKTERISTIKA A ZAJÍMAVÉ VÝSLEDKY KLINICKÝCH STUDIÍReview article

Miloslav Salavec1, Vanda Boštíková ORCID...2*, Nora Boštíková3, Pavel Boštík ORCID...2
1 Klinika nemocí kožních a pohlavních, FN a LF UK, Hradec Králové
2 Fakulta vojenského zdravotnictví v Hradci Králové, Univerzita obrany v Brně
3 Lékařská fakulta UK, Hradec Králové

Následující přehledový článek se souhrnně zabývá informacemi o chemoterapeutiku Dapson, a to z hlediska jeho chemické struktury, farmakologických vlastností, stejně jako informacemi čerpanými z klinických studií Dapsonu a jeho působení na zánětlivé procesy.

Keywords: Dapson; chemická struktura; farmakologie; antimikrobiální aktivita; protizánětlivé účinky

Received: July 17, 2017; Revised: July 26, 2017; Published: September 8, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Salavec, M., Boštíková, V., Boštíková, N., & Boštík, P. (2017). CHEMOTERAPEUTIKUM DAPSON - ZÁKLADNÍ CHARAKTERISTIKA A ZAJÍMAVÉ VÝSLEDKY KLINICKÝCH STUDIÍ. MMSL, 86(3), 114-121. doi: 10.31482/mmsl.2017.019
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ZHU, YL, STILLER, MJ. Dapson and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001 Sep, 45(3), 420-34. Go to original source... Go to PubMed...
    2. LANG, PG. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol. 1979, 1, 479-492. Go to original source... Go to PubMed...
    3. AL-SAID, MS., GHORAB, MM., NISSAN, YM. Dapson heterocytic chemistry, part VIII: synthesis, molecular docking and anticancer activity of some novel sulfonylbiscompounds carrying biologically active 1,3-dihydropyridine, chromene and chromenopyridine moieties. Chem Cent J. 2012, 6, 64. Go to original source... Go to PubMed...
    4. WOZEL, G., BLASUM, CH. Dapson in dermatology and beyond. Arch Dermatol Res. 2014, 306 (2), 103-124. Go to original source... Go to PubMed...
    5. SALAVEC, M. Autoimunitní subepidermální bulózní onemocnění - část II. Ostatní subepidermální puchýřnaté autoimunitní dermatózy - dermatitis herpetiformis, lineární IgA bulózní dermatóza, epidermolysis bullosa acquisita. Referátový výběr z dermatovenerologie, Speciál 1/2013, 35-47.
    6. PARK, BK., BOOBIS, A., CLARKE, S. et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov. 2011, 10, 292-306. Go to original source... Go to PubMed...
    7. BOZEMAN, PM., LEARN, DB, THOMAS, EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapson. Biochem Pharmacol. 1992, 44, 553-563. Go to original source...
    8. WOLFF, K. Subcorneal pustular dermatosis is not pustular psoriasis. Am J Dermatopathol. 1981, 3, 381-382. Go to original source... Go to PubMed...
    9. NISHINA, M., SAITO, E., KINOSHITA, M. Correction of severe leukopenia and thrombocytopenia in systemic lupus erythematosus by treatment with dapson. J Rheumatol. 1997, 24, 811-812. Go to PubMed...
    10. UETRECHT, J., ZAHID, N., SHEAR, NH. et al. Metabolism of dapson to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther. 1988, 245, 274-279. Go to PubMed...
    11. WOZEL, G. Dapson-Pharmakologie. Thieme, Stuttgart: Wirkmechanismus und klinischer Einsatz; 1996.
    12. CHO, SC., RHIM, JH, SON, YH. et al. Suppression of ROS generation by 4,4-diaminodiphenylsulfone in non-phagocytic human diploid fibroblasts. Exp Mol Med. 2010, 42, 223-232. Go to original source... Go to PubMed...
    13. CHEN, XY, BUSCHMANN, H., BOLM, C. Sulfoximine- and sulfilimine-based DAPSON analogs: syntheses and bioactivities. Synlett. 2012, 23, 2808-2810.
    14. LOPEZ-GOMEZ, M., CORONA, T., DIAZ-RUIZ, A. et al. Safety and tolerability of dapson for the treatment of patients with drug-resistant, partial-onset seizures: an open-label trial. Neurol Sci. 2011, 32, 1063-1067. Go to original source... Go to PubMed...
    15. MANGELSDORF, H., WHITE, W., JORIZZO, J. Behcet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. J Am Acad Dermatol. 1996, 34, 745-750. Go to original source... Go to PubMed...
    16. NICOLAS, MEO., KRAUSE, PR., GIBSON, LE. et al. Dermatitis herpetiformis - Review. Int J Dermatol, 2003, 42, 588-600. Go to original source... Go to PubMed...
    17. NIWA, Y., SAKANE, T., MIYACHI, Y. Dissociation of the inhibitory effect of dapson on the generation of oxygen intermediates-in comparison with that of colchicine and various scavengers. Biochem Pharmacol. 1984, 33, 2355-2360. Go to original source... Go to PubMed...
    18. NIWA, Y., MIYACHI, Y. Inhibitor effects of dapson on enzymatic acitivities of membrane phospholipids in human blood cells. Arch Dermatol Res. 1985, 277, 473-477. Go to original source... Go to PubMed...
    19. DRAYER, DE, STRONG, JM., JONES, B. et al. In vitro acetylation of drugs by human blood cells. Drug Metab Dispos. 1974, 2, 499-505.
    20. NIIMI, Y., KAWANA, S., KUSUNOKI, T. IgA pemphigus: A case report and its characteristic clinical features compared with subcorneal pustular dermatosis. J Am Acad Dermatol. 2000, 43, 546-549. Go to original source... Go to PubMed...
    21. THUONG-NGUYEN, V., KADUNCE, DP, HENDRIX, JD. et al. Inhibition of neutrophil adherence to antibody by dapson: a possible therapeutic mechanism of dapson in the treatment of IgA dermatoses. J Invest Dermatol. 1993, 100, 349-355. Go to original source... Go to PubMed...
    22. RUZICKA, T., GOERZ, G. Dapson in the treatment of lupus erythematosus. Br J Dermatol. 1981, 104, 53-56. Go to original source... Go to PubMed...
    23. RUZICKA, T., WASSERMAN, SI., SOTER, NA. et al. Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapson. J Allergy Clin Immunol. 1983, 72, 365-370. Go to original source... Go to PubMed...
    24. JEFFES, E., AHMED, A. Adjuvant therapy of bullous pemphigoid with dapson. Clin Exp Dermatol. 1989, 14, 132-136. Go to original source... Go to PubMed...
    25. SCHMIDT, E., REIMER, S., KRUSE, N. et al. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapson. Clin Exp Immunol. 2001, 124, 157-162. Go to original source... Go to PubMed...
    26. ABE, M., SHIMIZU, A., YOKOYAMA, Y. et al. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus. Clin Exp Dermatol. 2008, 33, 759-763. Go to original source... Go to PubMed...
    27. SCHADENDORF, D, HAAS, N., NURNBERGER, F. et al. Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapson therapy [letter]. Hautarzt. 1993, 44, 653-657. Go to PubMed...
    28. RIOS, C., NADER-KAWACHI, J., RODRIGUEZ-PAYÁN, AJ. et al. Neuroprotective effect of dapson in an occlusive model of focal ischemia in rats. Brain Res. 2004, 999, 212-215.
    29. SHIBATA K., TATEISHI T., YAMASAKI R., OHYAGI Y., KIRA J. Successful treatment of a case of steroid-dependent neuro-Sweet disease with dapsone. Rinsho Shinkeigaku. 2010, 50(4):257-61. Go to original source... Go to PubMed...
    30. POULSEN, A., HULTBERG, B., THOMSEN, K. et al. Dapson in the treatment of Kaposi's sarcoma. Acta Derm Venereol (Stockh). 1984, 64, 561-563.
    31. LAMMERS, AM., VAN DE KERKHOF, PC, SCHALWIJK, J. et al. Elastase, a marker for neutrophils in skin infiltrates. Br J Dermatol. 1986, 115, 181-186. Go to original source... Go to PubMed...
    32. RUBAIHAYO J., TUMWESIGYE NM., KONDE-LULE J. Trends in prevalence of selected opportunistic infections associated with HIV/AIDS in Uganda. BMC Infect Dis. 2015. 15: 187. Go to original source... Go to PubMed...

    Return to the content